Indicated Prevention of Psychotic Disorders With Long-Chainomega-3 Fatty Acids: A Randomized, Placebo-Controlled Trial

Amminger, G. Paul; Schäfer, Miriam R.; Παπαγεωργίου, Κ.; Harrigan, Susy; Cotton, Sue; McGorry, Patrick; Berger, Gregor

doi:10.1016/s0920-9964(08)70758-8

Cited by 56 publications

(68 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A promising study in young adults aged 13 to 25 years with subthreshold psychosis showed that 12-weeks omega-3 fatty acid supplementation reduced progression to psychotic disorder and general psychiatric morbidity over multiple years (Amminger et al 2010;Amminger et al 2015). However, the multicenter NEURAPRO study failed to replicate these initial hopeful findings (McGorry et al 2017).…”

Section: Clinical Applicationsmentioning

confidence: 99%

Focus on fatty acids in the neurometabolic pathophysiology of psychiatric disorders

Mocking

Assies

Ruhé

et al. 2018

J of Inher Metab Disea

View full text Add to dashboard Cite

Continuous research into the pathophysiology of psychiatric disorders, such as major depressive disorder (MDD), posttraumatic stress disorder (PTSD), and schizophrenia, suggests an important role for metabolism. This narrative review will provide an upto-date summary of how metabolism is thought to be involved in the pathophysiology of these psychiatric disorders. We will focus on (I) the important role of fatty acids in these metabolic alterations, (II) whether fatty acid alterations represent epiphenomena or risk factors, and (III) similarities and dissociations in fatty acid alterations between different psychiatric disorders. (Historical) epidemiological evidence links fatty acid intake to psychiatric disorder prevalence, corroborated by altered fatty acid concentrations measured in psychiatric patients. These fatty acid alterations are connected with other concomitant pathophysiological mechanisms, including biological stress (hypothalamic-pituitary-adrenal (HPA)-axis and oxidative stress), inflammation, and brain network structure and function. Metabolomics and lipidomics studies are underway to more deeply investigate this complex network of associated neurometabolic alterations. Supplementation of fatty acids as disease-modifying nutraceuticals has clinical potential, particularly add-on eicosapentaenoic acid (EPA) in depressed patients with markers of increased inflammation. However, by interpreting the observed fatty acid alterations as partly (mal)adaptive phenomena, we attempt to nuance translational expectations and provide new clinical applications for these novel neurometabolic insights, e.g., to predict treatment response or depression recurrence. In conclusion, placing fatty acids in context can contribute to further understanding and optimized treatment of psychiatric disorders, in order to diminish their overwhelming burden of disease.

show abstract

Section: Clinical Applicationsmentioning

confidence: 99%

Focus on fatty acids in the neurometabolic pathophysiology of psychiatric disorders

Mocking

Assies

Ruhé

et al. 2018

J of Inher Metab Disea

View full text Add to dashboard Cite

show abstract

“…Over a 52 week period, psychosis emerged in 27.5% of the control group, but in only 4.9% of the omega-3 group (Amminger et al, 2010). Although findings are inconsistent (Fusar-Poli &…”

Section: Alternative Treatments For Schizophreniamentioning

confidence: 97%

Will the Treatment Protocols for Schizophrenia be Changing Soon?

Littrell

2014

Social Work in Mental Health

View full text Add to dashboard Cite

In recent decades the understanding of the core physiology giving rise to schizophrenia has advanced markedly. Current pharmacological interventions fail to target the core problems in schizophrenia. Several important outcome studies call into question whether current medications actually make long term outcomes worse. These new studies follow the recognized negative side effect of anti-psychotic drugs. The implication of these findings for social workers who work with the seriously mentally ill are discussed. Alternatives to current pharmacological treatments which are more targeted toward the core physiology of schizophrenia are reviewed.

show abstract

“…This is because there are no controlled studies on the use of medication in youth with BPD or BPD symptoms. More recently, a single trial [131] has reported significant benefit from omega-3 polyunsaturated fatty acids (PUFAs) for adolescents with BPD and psychotic features. Two observational studies have examined small (<15 youth) samples of adolescents with BPD over 2-3 months.…”

Section: Treatment Bpdmentioning

confidence: 99%

Borderline personality disorder in children and adolescents: discriminant validity in relation to major depressive disorder

Boylan¹,

Dyce²,

Semovski³

2017

J Psychol Psychiatry

View full text Add to dashboard Cite

Clinical discernment of the diagnosis of borderline personality disorder (BPD) in adolescents is difficult, due in part to very high rates of comorbidity with major depressive disorder (MDD) or depressive symptoms. This paper reviews published research on studies about risk factors, neurobiological and neuropsychological correlates and treatment in both disorders for persons less than 25 years of age. The aim is to focus on differences identified between the disorders to substantiate their discriminative validity, although similarities are included. Very few studies were found which directly compared youth with both disorders -or both disorders -in the same sample. These studies found strong covariation between BPD and MDD symptoms across adolescence and conjoint response to dialectical behavioural therapy. Youth with BPD may have greater impairments in social processing than youth with MDD. Indirect comparisons supported poor evidence for discriminative validity and no findings were replicated. To date, the limited research base does not support that BPD and MDD are distinct disorders in adolescence, however the absence of observed differences is not the same as evidence of no difference. Given the importance of improving psychiatric and psychological care for youth, it is strongly recommended that studies about adolescent mood and mood disorder include concurrent and repeated measurement of BPD and MDD.

show abstract

Indicated Prevention of Psychotic Disorders With Long-Chainomega-3 Fatty Acids: A Randomized, Placebo-Controlled Trial

Cited by 56 publications

References 0 publications

Focus on fatty acids in the neurometabolic pathophysiology of psychiatric disorders

Focus on fatty acids in the neurometabolic pathophysiology of psychiatric disorders

Will the Treatment Protocols for Schizophrenia be Changing Soon?

Borderline personality disorder in children and adolescents: discriminant validity in relation to major depressive disorder

Contact Info

Product

Resources

About